Katia Karalis Selected Research

Clostridium difficile tcdA protein

9/2007	Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha.
9/2006	Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses.
6/2004	Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation.
3/2003	Leptin mediates Clostridium difficile toxin A-induced enteritis in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katia Karalis Research Topics

Disease

5	Inflammation (Inflammations) 09/2006 - 08/2002
4	Colitis 01/2021 - 03/2003
3	Diarrhea 09/2006 - 03/2003
2	Infections 11/2020 - 11/2020
1	Neoplasms (Cancer) 11/2021
1	Gliosis 10/2021
1	Synucleinopathies 10/2021
1	Parkinson Disease (Parkinson's Disease) 10/2021
1	Weight Gain 01/2021
1	Adenoma (Adenomas) 01/2021
1	Obesity 01/2021
1	Tuberculosis (Tuberculoses) 11/2020
1	Virus Diseases (Viral Diseases) 11/2020
1	Asthma (Bronchial Asthma) 11/2020
1	Hyperplasia 11/2020
1	Thrombosis (Thrombus) 12/2018
1	Ulcerative Colitis 09/2007
1	Necrosis 09/2007
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 09/2007
1	Pseudomembranous Enterocolitis (Pseudomembranous Colitis) 06/2004
1	Coronary Artery Disease (Coronary Atherosclerosis) 07/2003
1	Acute Coronary Syndrome 07/2003
1	Enteritis 03/2003
1	Edema (Dropsy) 08/2002

Drug/Important Bio-Agent (IBA)

4	Clostridium difficile tcdA proteinIBA 09/2007 - 03/2003
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2007
3	Enterotoxins (Enterotoxin)IBA 09/2006 - 03/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2007 - 08/2002
2	Messenger RNA (mRNA)IBA 09/2007 - 09/2006
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2006 - 03/2003
2	Corticotropin-Releasing HormoneIBA 06/2004 - 08/2002
1	Neoplasm Antigens (Tumor Antigens)IBA 11/2021
1	Bispecific AntibodiesIBA 11/2021
1	alpha-SynucleinIBA 10/2021
1	Sucrase (Sucrose alpha-D-Glucohydrolase)IBA 01/2021
1	Interleukin-22 (IL-22)IBA 01/2021
1	Oligo-1,6-Glucosidase (Isomaltase)IBA 01/2021
1	Surface-Active Agents (Surfactants)IBA 11/2020
1	Pulmonary Surfactants (Pulmonary Surfactant)IBA 11/2020
1	2- hydroxy- N,N- dimethyl- 3- (2- ((1- (5- methylfuran- 2- yl)propyl)amino)- 3,4- dioxocyclobut- 1- enylamino)benzamideIBA 11/2020
1	Interleukin-13IBA 11/2020
1	FibrinIBA 12/2018
1	CD40 Ligand (CD40L)IBA 12/2018
1	Monoclonal AntibodiesIBA 12/2018
1	Thrombin FDA Link 12/2018
1	MitogensIBA 09/2007
1	Phosphotransferases (Kinase)IBA 09/2007
1	NF-KappaB Inhibitor alphaIBA 09/2007
1	NF-kappa B (NF-kB)IBA 09/2007
1	Chemotactic FactorsIBA 09/2006
1	ChemokinesIBA 09/2006
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 09/2006
1	Substance PIBA 06/2004
1	Interleukin-6 (Interleukin 6)IBA 07/2003
1	LeptinIBA 03/2003
1	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2003
1	Interleukin-1beta (Interleukin 1 beta)IBA 08/2002
1	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA 08/2002

Therapy/Procedure

1	Immunotherapy 11/2021
1	Therapeutics 10/2021
1	Glycemic Control 01/2021
1	Immunomodulation 11/2020
1	Adrenalectomy 03/2003